Neuropathy Less Severe, Frequent With Eribulin vs Paclitaxel

However, among patients with invasive breast cancer, pathologic complete response rates with eribulin were lower. The study was published as a preprint and has not yet been peer reviewed.

Related Keywords

, Breast Cancer , Alignant Breast Neoplasm , Chemotherapy , Neoadjuvant , Neuropathy , Peer Review , Neurotoxicity , Sensory Neuropathy , Toxicology ,